ArticleFrontiers in neurology2026
Salvianolic acid B alleviates depression-like behaviors by reducing neuronal injury and promoting neurogenesis in a manner associated with JAK-STAT signaling pathway inhibition.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Depression is strongly associated with hippocampal neuroinflammation, neuronal damage and neurogenesis. Salvianolic acid B (SalB) has anti-inflammatory and neuroprotective potential, but whether its antidepressant effect is achieved by regulating the JAK-STAT signaling pathway has not been systematically studied. Methods: HT22 cell injury was induced by corticosterone (CORT) and treated with SalB. The appropriate intervention dose was screened by CCK-8 assay. The degree of cell damage was detected by flow cytometry, ELISA and kit. A chronic unpredictable mild stress (CUMS) model of depression was induced, and behavioral tests were performed. Neuronal damage, microglia activation, neuronal apoptosis, neurogenesis and synaptic plasticity were detected by ELISA, immunofluorescence, immunohistochemistry, Nissl staining and Golgi-Cox staining. The activity of JAK-STAT pathway in hippocampus and cells was detected. Results: HT22 cells were exposed to 10, 15, and 20 μM SalB and 200 μM CORT, respectively. SalB inhibited CORT-induced release of inflammatory factors, oxidative stress and apoptosis. In CUMS mice, SalB significantly improved depression-like behavior, inhibited excessive activation of microglia, reduced neuroinflammation and hippocampal neuronal apoptosis, protected Nissl body structure and mature neurons, promoted neurogenesis and improved dendritic spine density and synaptic protein expression. In addition, SalB also inhibited JAK-STAT signaling, and pathway activator RO8191 reversed the neuroprotective effect of SalB. Conclusion: SalB exerted multiple protective effects against neuroinflammation, neuronal apoptosis and neurogenesis in a manner associated with inhibition of the JAK-STAT signaling pathway, and ultimately improved depression-like behavior.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.